Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study.
Fiche publication
Date publication
mai 2019
Journal
Multiple sclerosis and related disorders
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Miller AE, Vermersch P, Kappos L, Comi G, Freedman MS, Oh J, de Seze J, Truffinet P, Benamor M, Purvis A, Wolinsky JS,
Lien Pubmed
Résumé
In the phase 3 TOPIC study, teriflunomide significantly reduced the risk of relapse determining conversion to clinically definite multiple sclerosis (CDMS) in patients with clinically isolated syndrome, versus placebo. We assessed clinical and safety outcomes associated with extended teriflunomide treatment in the TOPIC extension study.
Mots clés
Clinically definite multiple sclerosis, Clinically isolated syndrome, Early multiple sclerosis, Relapse rate, Teriflunomide
Référence
Mult Scler Relat Disord. 2019 May 24;33:131-138